Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacokinet
Autores principales: Verheijen, Remy B., Atrafi, Florence, Schellens, Jan H. M., Beijnen, Jos H., Huitema, Alwin D. R., Mathijssen, Ron H. J., Steeghs, Neeltje
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5904242/
https://ncbi.nlm.nih.gov/pubmed/28762135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0582-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares